Delayed gametocyte clearance in Plasmodium vivax malaria is associated with polymorphisms in the cytochrome P450 reductase (CPR)

Antimicrob Agents Chemother. 2024 Apr 3;68(4):e0120423. doi: 10.1128/aac.01204-23. Epub 2024 Feb 27.

Abstract

Primaquine (PQ) is the main drug used to eliminate dormant liver stages and prevent relapses in Plasmodium vivax malaria. It also has an effect on the gametocytes of Plasmodium falciparum; however, it is unclear to what extent PQ affects P. vivax gametocytes. PQ metabolism involves multiple enzymes, including the highly polymorphic CYP2D6 and the cytochrome P450 reductase (CPR). Since genetic variability can impact drug metabolism, we conducted an evaluation of the effect of CYP2D6 and CPR variants on PQ gametocytocidal activity in 100 subjects with P. vivax malaria. To determine gametocyte density, we measured the levels of pvs25 transcripts in samples taken before treatment (D0) and 72 hours after treatment (D3). Generalized estimating equations (GEEs) were used to examine the effects of enzyme variants on gametocyte densities, adjusting for potential confounding factors. Linear regression models were adjusted to explore the predictors of PQ blood levels measured on D3. Individuals with the CPR mutation showed a smaller decrease in gametocyte transcript levels on D3 compared to those without the mutation (P = 0.02, by GEE). Consistent with this, higher PQ blood levels on D3 were associated with a lower reduction in pvs25 transcripts. Based on our findings, the CPR variant plays a role in the persistence of gametocyte density in P. vivax malaria. Conceptually, our work points to pharmacogenetics as a non-negligible factor to define potential host reservoirs with the propensity to contribute to transmission in the first days of CQ-PQ treatment, particularly in settings and seasons of high Anopheles human-biting rates.

Keywords: CYP2D6; Plasmodium vivax; cytochrome P450 reductase; gametocytes; malaria; pharmacogenetics; primaquine.

MeSH terms

  • Antimalarials* / pharmacology
  • Antimalarials* / therapeutic use
  • Artemisinins* / pharmacology
  • Chloroquine / pharmacology
  • Cytochrome P-450 CYP2D6 / genetics
  • Humans
  • Malaria* / drug therapy
  • Malaria, Falciparum* / drug therapy
  • Malaria, Vivax* / drug therapy
  • NADPH-Ferrihemoprotein Reductase
  • Plasmodium falciparum
  • Plasmodium vivax / genetics
  • Primaquine / pharmacology
  • Primaquine / therapeutic use

Substances

  • Antimalarials
  • NADPH-Ferrihemoprotein Reductase
  • Chloroquine
  • Cytochrome P-450 CYP2D6
  • Artemisinins
  • Primaquine